Semaglutide acetate salt
Semaglutide acetate salt structure
|
Common Name | Semaglutide acetate salt | ||
|---|---|---|---|---|
| CAS Number | 910463-68-2 | Molecular Weight | 4113.57754 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C187H291N45O59 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Semaglutide acetate saltSemaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes. |
This table lists Chinese names, IUPAC names and various aliases of this chemical substance.
| Name | Sermaglutide |
|---|
This table contains bioactivity, target information and biological‑assay experimental data of this compound.
| Description | Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes. |
|---|---|
| Related Catalog | |
| Target |
GLP-1 receptor[1]. |
| In Vitro | Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1[3. |
| In Vivo | The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs[1]. Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters[2]. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight[3]. |
| Animal Admin | Mice[2] Male C57BL/6 mice 10 weeks old (20-25 g) are used throughout the study. Mice are randomized divided into six groups (n=12 per group) (i) control group treated with saline alone; (ii) liraglutide group treated with saline and liraglutide (25 nmol/kg ip. once daily for 7 days); (iii) Semaglutide group treated with saline and Semaglutide (25 nmol/kg ip. once daily for 7 days), (iv) MPTP group treated with MPTP alone (once daily 20 mg/kg ip. for 7 days); (v) MPTP (once daily 20 mg/kg ip. for 7 days) followed immediately by liraglutide treated group (25 nmol/kg ip. once daily for 7 days). (vi) MPTP (20 mg/kg ip. once daily for 7 days) followed immediately by Semaglutide treated group (25 nmol/kg ip. Once daily for 7 days). At the end of drug treatments, measure the behavioral changes, neuronal damage, inflammatory markers, and other biomarkers[2]. |
| References |
[3]. Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284. |
This table shows physicochemical parameters including melting point, boiling point, density, solubility and optical rotation. Missing data is marked as N/A.
| Molecular Formula | C187H291N45O59 |
|---|---|
| Molecular Weight | 4113.57754 |
| InChIKey | DLSWIYLPEUIQAV-VMBHQQOKSA-N |
| SMILES | CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C |
| Storage condition | -20°C |
This table covers safety warnings, protective measures, incompatible substances and disposal guidelines for this compound.
| Hazard Codes | Xi |
|---|
This table contains target information, in‑vitro & in‑vivo assay data for this compound.
|
Name: Human GLP-1 receptor (Glucagon receptor family)
Source: IUPHAR-DB
Target: GLP-1 receptor (Glucagon receptor family) [Homo sapiens]
External Id: 249_Human
|
This section contains frequently‑asked‑questions about this compound, including basic parameters, properties, storage conditions and corresponding answers.
| Q: What is the English name of Sermaglutide? |
| A: The English name of Sermaglutide is Sermaglutide. |
| Q: What is the CAS number of Sermaglutide? |
| A: CAS number of Sermaglutide is 910463-68-2. |
| Q: What are the storage conditions for Sermaglutide? |
| A: Storage conditions for Sermaglutide: -20°C. |
| Q: What is the InChIKey of Sermaglutide? |
| A: InChIKey of Sermaglutide is DLSWIYLPEUIQAV-VMBHQQOKSA-N. |
| Q: What is the molecular formula of Sermaglutide? |
| A: Molecular formula of Sermaglutide is C187H291N45O59. |
| Q: What are the uses of Sermaglutide? |
| A: Main uses of Sermaglutide: Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes. |
| Q: What is the molecular weight of Sermaglutide? |
| A: Molecular weight of Sermaglutide is 4113.57754. |
This table lists manufacturers and suppliers of this compound, including vendor names and product supply reference information.
| Shanghai Nianxing Industrial Co., Ltd |
| Henan Tianfu Chemical Co., Ltd. |